These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9669632)

  • 21. Discrimination of irritable bowel syndrome by non-linear analysis of 24-h jejunal motility.
    Wackerbauer R; Schmidt T; Widmer R; Pfeiffer A; Morfill G; Kaess H
    Neurogastroenterol Motil; 1998 Aug; 10(4):331-7. PubMed ID: 9697107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current concepts in the management of the irritable bowel syndrome.
    Snape WJ
    Rev Gastroenterol Mex; 1994; 59(2):127-32. PubMed ID: 7991965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fructose-sorbitol malabsorption and symptom provocation in irritable bowel syndrome: relationship to enteric hypersensitivity and dysmotility.
    Evans PR; Piesse C; Bak YT; Kellow JE
    Scand J Gastroenterol; 1998 Nov; 33(11):1158-63. PubMed ID: 9867093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit.
    Song CW; UM SH; Kim CD; Ryu HS; Hyun JH; Choe JG
    Scand J Gastroenterol; 1997 Jun; 32(6):541-6. PubMed ID: 9200284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.
    Hatlebakk JG; Johnsson F; Vilien M; Carling L; Wetterhus S; Thøgersen T
    Scand J Gastroenterol; 1997 Nov; 32(11):1100-6. PubMed ID: 9399390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
    Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
    Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug treatment options for irritable bowel syndrome: managing for success.
    Dunphy RC; Verne GN
    Drugs Aging; 2001; 18(3):201-11. PubMed ID: 11302287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.
    Wiseman LR; Faulds D
    Drugs; 1994 Jan; 47(1):116-52. PubMed ID: 7510617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder.
    Camilleri M; Balm RK; Zinsmeister AR
    Gastroenterology; 1994 Apr; 106(4):916-23. PubMed ID: 8143996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome.
    Larsson MH; Simrén M; Thomas EA; Bornstein JC; Lindström E; Sjövall H
    Neurogastroenterol Motil; 2007 Oct; 19(10):812-20. PubMed ID: 17883433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of cisapride on postcibal jejunal motor activity.
    Stacher G; Gaupmann G; Steinringer H; Schneider C; Stacher-Janotta G; Steiner-Mittelbach G; Abatzi TA
    Dig Dis Sci; 1989 Sep; 34(9):1405-10. PubMed ID: 2766908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to intraluminal gas in irritable bowel syndrome. Motility versus perception.
    Galati JS; McKee DP; Quigley EM
    Dig Dis Sci; 1995 Jun; 40(6):1381-7. PubMed ID: 7781464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cisapride on chronic idiopathic constipation in children.
    Staiano A; Cucchiara S; Andreotti MR; Minella R; Manzi G
    Dig Dis Sci; 1991 Jun; 36(6):733-6. PubMed ID: 2032513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome.
    Gorard DA; Libby GW; Farthing MJ
    Gut; 1994 Feb; 35(2):203-10. PubMed ID: 8307470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)].
    Simrén M; Castedal M; Svedlund J; Abrahamsson H; Björnsson E
    Dig Dis Sci; 2000 Nov; 45(11):2151-61. PubMed ID: 11215731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity.
    Gonlachanvit S; Mahayosnond A; Kullavanijaya P
    Neurogastroenterol Motil; 2009 Jan; 21(1):23-32. PubMed ID: 18647268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cisapride on distal colonic motility in the early postoperative period following left colonic anastomosis.
    Roberts JP; Benson MJ; Rogers J; Deeks JJ; Wingate DL; Williams NS
    Dis Colon Rectum; 1995 Feb; 38(2):139-45. PubMed ID: 7851167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux.
    Vaezi MF; Sears R; Richter JE
    Dig Dis Sci; 1996 Apr; 41(4):754-63. PubMed ID: 8674397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.